UPDATE: Ascendiant Capital Initiates Coverage on Galectin Therapeutics on Intriguing Speculative Short-Cap Investment Story
October 07, 2013 at 10:55 AM EDT
In a report published Monday, Ascendiant Capital Markets analyst Keay Nakae initiated coverage on Galectin Therapeutics (NASDAQ: GALT ) with a Buy rating and $13.00 price target. In the report, Ascendiant Capital Markets noted, “We are initiating coverage of GALT with a Buy rating and 12-month price target of $13.00.
